The density of CD169⁺ macrophages has been reported to positively correlate with the number of CD8⁺ T cells, although this remains controversial. To better understand this topic, we conducted a meta-analysis. We searched the PubMed, Medline, and Web of Science databases for studies that were published before May 2022 and performed a meta-analysis of the incidence of low and high CD169 expression in groups based on CD8 expression using the random-effects model. A total of 10 studies were included in the meta-analysis. The incidence of high CD169 expression in lymph nodes was significantly lower than that of low CD169 expression in the low CD8 expression group (odds ratio (OR): 0.76, 95% confidence interval (CI): 0.6, 0.96); however, the incidence of high CD169 expression in lymph nodes was higher than that of low CD169 expression in the high CD8 expression group (OR: 1.50, 95% CI: 1.08, 2.07). We also found that the expression of CD169 in tumors was lower than that in nontumor tissues (standardized mean difference: −5.29, 95% CI: −7.47, −3.11). The overall survival and hazard ratio of patients with high and low CD169 expression was 0.45 (95% CI: 0.37, 0.55). This analysis showed that high CD169 expression was associated with a high CD8 expression, and low CD169 expression was associated with low CD8 expression. The risk of death was 55% lower for patients with high CD169 expression, and high CD169 expression may be associated with favorable survival outcomes in cancer patients. However, the number and heterogeneity of the studies should be taken into consideration when evaluating the analysis. High-quality randomized controlled trials on the association between CD169 and CD8 expression are needed to verify these effects.

中文翻译：

---

淋巴结中 CD169 的表达与肿瘤中 CD8+ T 细胞浸润增加相关：系统评价和荟萃分析

据报道， CD169 ⁺巨噬细胞的密度与 CD8 ⁺ T 细胞的数量呈正相关，尽管这仍然存在争议。为了更好地理解这个主题，我们进行了荟萃分析。我们检索了 PubMed、Medline 和 Web of Science 数据库中 2022 年 5 月之前发表的研究，并使用随机效应模型对基于 CD8 表达的组中 CD169 低表达和高表达的发生率进行了荟萃分析。荟萃分析中总共纳入了 10 项研究。淋巴结中CD169高表达的发生率显着低于CD8低表达组中CD169低表达的发生率（比值比（OR）：0.76，95%置信区间（CI）：0.6，0.96）；然而，CD8高表达组淋巴结中CD169高表达的发生率高于CD169低表达的发生率（OR：1.50，95％CI：1.08，2.07）。我们还发现肿瘤中CD169的表达低于非肿瘤组织（标准化平均差：-5.29，95％CI：-7.47，-3.11）。CD169高表达和低表达患者的总生存率和风险比为0.45（95% CI：0.37，0.55）。该分析表明高CD169表达与高CD8表达相关，低CD169表达与低CD8表达相关。CD169 高表达的患者死亡风险降低 55%，并且 CD169 高表达可能与癌症患者良好的生存结果相关。然而，在评估分析时应考虑研究的数量和异质性。需要对 CD169 和 CD8 表达之间的关联进行高质量随机对照试验来验证这些效果。